CN88 A phase II randomized trial of nurse led telehealth follow-up including patient reported outcomes using the MOST-S26 (measure of ovarian symptoms and treatment concerns) versus routine clinic based or telehealth follow-up, after completion of chemotherapy in patients with ovarian cancer
Paul A. Cohen(The University of Western Australia), M.L. Friedlander(Prince of Wales Hospital), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Andrew Ddembe Kiberu, Jeffrey C. Goh(Royal Brisbane and Women's Hospital), Val Gebski(The University of Sydney), Rachael L. Morton(University of Sydney), Linda Mileshkin(Peter MacCallum Cancer Centre), A. Mellon(Hunter New England Local Health District), Jim Codde(The University of Notre Dame Australia), Tarek Meniawy(St John of God Subiaco Hospital), Angela Ives(The University of Western Australia), William Lawson(George Washington University), Ross Campbell(University of Ottawa), A. Brand(Westmead Hospital), Phyllis Butow(Royal Prince Alfred Hospital), Sanela Bilic, Andreas Obermair(Royal Brisbane and Women's Hospital), Orla McNally(Royal Women's Hospital), Madeleine King(The University of Sydney)
Cited by 0
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
|Journal of Thoracic Oncology|2016|842
Type I and II Endometrial Cancers: Have They Different Risk Factors?
|Journal of Clinical Oncology|2013|833